Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com - KeyBanc Capital Markets maintained its Overweight rating and $325.00 price target on West Pharmaceutical (NYSE:WST) following the company’s quarterly results. According to InvestingPro data, the stock has seen strong momentum with a 24.95% return over the past week, while analysts’ targets range from $245 to $350.
West Pharmaceutical reported 6.8% organic growth in the second quarter, with its Proprietary Products segment growing 8.4% and high-value product elastomer components increasing 11.3%. The company, currently valued at $18.95 billion, maintains a solid financial health score of "GOOD" according to InvestingPro analysis, which includes 15+ additional insights available to subscribers.
The firm noted that GLP-1 drugs are creating significant momentum for West Pharmaceutical, with related products growing 60% and now representing 8% of overall revenue, up from mid-single digits previously.
Despite West Pharmaceutical maintaining its full-year 2025 organic growth guidance of approximately 3%, KeyBanc expects the company to exceed these projections in the second half of the year.
KeyBanc projects that West Pharmaceutical will achieve its long-term organic growth target of 7-9% by 2026, with the firm specifically estimating 7% organic growth for fiscal year 2026.
In other recent news, West Pharmaceutical Services Inc . reported impressive financial results for the second quarter of 2025. The company exceeded analyst expectations with an earnings per share (EPS) of $1.84, surpassing the anticipated $1.51, which represents a 21.85% surprise. Additionally, West Pharmaceutical’s revenue reached $766.5 million, outpacing the forecasted $725.26 million by 5.69%. These robust earnings results have drawn positive attention from investors. In a related development, Evercore ISI raised its price target for West Pharmaceutical to $350 from $275, while maintaining an Outperform rating. The research firm highlighted the company’s strong performance amid challenging macroeconomic conditions as a reason for the target increase. These recent developments underscore West Pharmaceutical’s resilience and ability to deliver strong financial outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.